<DOC>
	<DOCNO>NCT00005833</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness R115777 treat patient recurrent advanced colorectal cancer .</brief_summary>
	<brief_title>S9923 R115777 Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate R115777 patient disseminate colorectal cancer previously treat advanced disease . II . Assess time treatment failure survival patient treatment regimen . III . Determine frequency severity toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral R115777 twice daily day 1-21 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study 5-7 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced colorectal adenocarcinoma Well differentiate OR Moderately well differentiate OR Poorly differentiate Distant metastasis surgically curable Measurable disease No prior treatment disseminate disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception Must able swallow receive enteral medication gastrostomy feed tube No intractable nausea vomit No prior malignancy past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior adjuvant immunotherapy recover No concurrent immunotherapy Chemotherapy : At least 4 week since prior adjuvant chemotherapy recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy recover No 25 % total area bone marrow irradiate No concurrent radiotherapy Surgery : At least 2 week since prior surgery recover Other : No concurrent proton pump inhibitor No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>